Pre-Close Trading Update

RNS Number : 3731H

Animalcare Group PLC

11 July 2012

 



Animalcare Group plc ("Animalcare" or the "Group")

Pre-Close Trading Update

Animalcare Group plc (AIM: ANCR), a leading supplier of veterinary medicines, provides a pre-close trading statement ahead of the publication of its results for the year to 30^th June 2012, which are expected to be broadly in-line with recently revised expectations.

Following the trends outlined in the trading update issued on 24^th May 2012, trading in Companion Animal Identification products and services remains difficult.  Some progress has however been made in the launch of new products and services using the modernised registration database.  Revenue for this product group will be slightly better than indicated in the May trading update, but still approximately 29% below those for year ending 30^th June 2011.

Revenue for the full year from our core Licensed Veterinary Medicines segment remained strong.  Excluding the impact of the temporary disruption to the supply of Buprecare ampoules, revenue in this segment is approximately 17% ahead of last year.  When the effects of the supply disruption are included, revenue for the segment was approximately 2% ahead of last year.

The Group's target of four new licensed veterinary medicines launches in the financial year was passed with a total of five products* launched.

As highlighted in the May update, whilst the sales of identification microchips and associated services are not expected to show an immediate rebound, the new database initiatives will continue to positively impact the Companion Animal Identification segment both in terms of revenue and improved cost efficiency. The Board remains confident that the Licensed Veterinary Medicines segment will continue to strengthen.

Full year results are expected to be announced on Thursday 4 October 2012.

For further information:

Animalcare Group plc
Stephen Wildridge (Chief Executive Officer)	Tel: [phone]
N+1 Brewin (Nominated Adviser and Broker)
Aubrey Powell	Tel: [phone]
Richard Lindley	Tel: [phone]
Walbrook PR Ltd	Tel: [phone]
Paul McManus	[e-mail]
Helen Westaway	[e-mail]

* Licensed veterinary products launchedduring the financial year are: Torphasol, an analgesic for equines; Detonervin, an equine sedative; Emdocam Equine, an anti-inflammatory for equines; Tilmodil, an antibiotic for cattle, and Buprecare multidose, an analgesic for cats and dogs.

 

END

 

 

MSCLLFERDLIILIF